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Abstract
Background: Follicular fluid (FF) is an important micro-environment influencing oocyte growth, its development
competence, and embryo viability. The FF content analysis allows to identify new relevant biomarkers, which could be
predictive of in vitro fertilization (IVF) outcomes. Inside ovarian follicle, the amount of FF components from granulosa
cells (GC) secretion, could be regulated by gonadotropins, which play a major role in follicle development.
Methods: This prospective study included 61 female undergoing IVF or Intra-cytoplasmic sperm injection (ICSI)
procedure. Apolipoprotein B (APOB) concentrations in follicular fluid and APOB gene and protein expression in
granulosa cells from reproductively aged women undergoing an in vitro fertilization program were measured. The
statistical analyses were performed according to a quartile model based on the amount of APOB level found in FF.
Results: Amounts of APOB were detected in human FF samples (mean ± SD: 244.6 ± 185.9 ng/ml). The odds of
obtaining an oocyte in the follicle and a fertilized oocyte increased significantly when APOB level in FF was higher than
112 ng/ml [i.e., including in Quartile Q 2, Q3 and Q4] (p = 0.001; p < 0.001, respectively). The probabilities of obtaining
an embryo and a top quality embryo on day 2, were significantly higher if APOB levels were within the ranges of 112
and 330 ng/ml (i.e. in Q2 and Q3) or 112 and 230 ng/ml (i.e. in Q2), respectively (p < 0.001; p = 0.047, respectively). In
addition, our experiments in vitro indicated that APOB gene and protein expression, along with APOB content into
culture were significantly under-expressed in GC upon stimulation with gonadotropins (follicular stimulating hormone:
FSH and/or human chorionic gonadotropin: hCG).
Conclusion: We are reporting a positive and statistically significant associations between APOB and oocyte retrieval,
oocyte fertilization, and embryo quality. Using an experimental study component, the authors report significant
reduced APOB expression and content for luteinized granulosa cells cultured in the presence of gonadotropins.
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Background
Apolipoprotein B (APOB) is a major structural protein
for atherogenic APOB-containing lipoproteins, including
chylomicrons, Very-Low-Density Lipoprotein (VLDL),
Intermediate-Density Lipoprotein (IDL) and Low-
Density Lipoprotein (LDL). The APOB-containing lipo-
proteins contain large amounts of cholesterol and
triglycerides (TG) and are involved in lipoprotein metab-
olism and plasma lipid transport [1–4].
These lipoproteins are secreted by enterocytes [5], he-
patocytes [6], human placenta [7] and cardiomyocytes
[8]. APOB synthesis and secretion are regulated by sev-
eral hormonal factors in hepatocytes such as Growth
Hormone [9], insulin [10], adrenocorticotrophic hor-
mone [11] and thyroid hormones [12]. Interestingly, we
demonstrated previously that human granulosa cells
(GC) are also able to assemble and secrete APOB100-
containing lipoproteins [13]. Although GC functions are
mostly influenced by gonadotropins, hormonal regulation
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of APOB expression in GC has never been investi-
gated. Follicular fluid (FF), surrounding oocyte, pro-
vides an important microenvironment, influencing
oocyte developmental competence and embryo devel-
opment [14–16]. Therefore, recent works focused on
FF analysis and identified in this fluid, potential bio-
markers, which could be used to assess oocyte/embryo
quality in order to improve the in vitro fertilization
(IVF) success rates [17, 18]. Only few studies reported
the presence of VLDL, LDL and APOB in human FF
[13, 19, 20] and thus their relationships with IVF out-
comes remain unknown.
This prospective translational study included two main
objectives. First, we performed APOB quantification in
individual FF samples (n = 201) from 61 patients under-
going IVF/Intra-cytoplasmic sperm injection (ICSI)
program in order to investigate relationships between
intra-follicular APOB levels and IVF/ICSI outcomes.
Secondly, we explored hormonal regulation by gonado-
tropins of APOB expression in cultured human GC. To
do so, in vitro studies were undertaken for which human
GC isolated from FF were stimulated or not with gonad-
otropins (FSH and/or hCG). The apolipoprotein B gene
and protein expressions in GC along with APOB content
of the culture medium were investigated.
Methods
Determination of APOB concentrations in blood-free FF
samples, obtained from 61 female patients
Patients' characteristics
A total of 61 female patients between 24 and 42 years of
age (mean ± SD: 33.6 ± 4.8 years) and with a BMI be-
tween 16 and 35 kg/m2 (mean ± SD: 22.5 ± 3.8 kg/m2)
were included in our prospective study. Among these
patients, 16 were overweight or obese (BMI >25 kg/m2),
whereas 3 were underweight (BMI < 18.5 kg/m2). These
women underwent controlled ovarian stimulation (COS)
followed by either IVF (n = 34) or ICSI (n = 27) proced-
ure at the Assisted Reproduction Technology Depart-
ment of the Dijon hospital (CHU de Dijon, France).
Exclusion criteria included polycystic ovary syndrome or
lipid metabolic disorders [21]. On average, the delay in
conception was 3.6 ± 1.8 years. Forty three couples had
primary infertility (70.5 %) and 18 couples secondary in-
fertility (29.5 %). Fifty five couples were enrolled in IVF/
ICSI procedure for the first or second time. Female in-
fertility, sperm abnormalities, mixed and unexplained in-
fertility were diagnosed in 49.2 %, 37.7 %, 8.2 %, and
4.9 % of the cases, respectively. Based on anti-müllerian
hormone (AMH) and antral follicular count (AFC), all
women had a normal ovarian reserve. The patients' clin-
ical characteristics are summarized in Additional file 1:
Table S1. Informed consents were obtained from all
patients for the use of FF samples on the day of oocyte
retrieval.
IVF/ICSI procedure
Sixty one patients underwent an agonist GnRH protocol
including ovarian stimulation with recombinant FSH (r-
FSH) (Puregon, Schering Plough, Courbevoie, France or
Gonalf, Merck Serono, Lyon, France). Ovarian stimula-
tion response was monitored by both, serum estradiol
concentration and transvaginal ultrasound assessment of
follicular and endometrial growth.
Ovulation was induced with 6500 UI of recombinant
hCG (Ovitrelle, Merck Serono, Lyon, France) when at
least three follicles had reached 17 mm or more in diam-
eter. Cumulus oocyte complexes (COC) were retrieved
by transvaginal ultrasound-guided aspiration, 36 h after
ovulation triggering, rinsed twice and isolated for con-
ventional IVF or ICSI protocol. In ICSI procedure, after
denudation, oocyte maturity was assessed and mature
oocytes were micro-injected. Oocytes were individually
maintained in 30 μl microdrops of culture medium (Glo-
bal Medium, LifeGlobal, USA) under oil at 37 °C in 6 %
CO2 and 5 % O2. Normal fertilization was checked be-
tween 16 and 18 h after insemination or microinjection
by the presence of two pronuclei (2PN) and the two
polar bodies. Early cleavage (EC) was evaluated 25 or
27 h after microinjection (ICSI) or insemination (IVF),
respectively. Two days after oocyte retrieval, embryo
quality was scored according to morphological criteria:
(i) cleavage stage, (ii) number and size of blastomeres,
and (iii) degree of fragmentation. An embryo was con-
sidered as a top quality embryo if there were 4 to 5 blas-
tomeres on day 2, less than 20 % of fragments, and no
multinucleation [22]. On day 2, the embryo(s) (standard-
of-care in the centre) was (were) transferred under
transabdominal ultrasound guidance.
APOB quantification by ELISA in individual FF samples
For the 61 patients, at the day of oocyte retrieval, all the
follicles visualized by ultrasound were aspirated individu-
ally without flushing. Only blood-free FF samples
(n = 201) were collected and centrifuged at 3000 g for
15 min. The supernatants were removed and stored at –
80 °C for APOB quantification. APOB concentration in
each FF sample was quantified using the Human APOB
ELISAprokit (no. 3715-1HP-2 Mabtech AB, Sophia Anti-
polis, France). Inter and intra-assay variation coefficients
were 10.0 % (CV) and 2.0 % (CV), respectively.
Quartile model
Quartiles (Q) of APOB concentrations (ng/ml) measured
in the FF (n = 201) samples of the 61 patients were de-
fined as followed:
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Q1: APOB <112 ng/ml
Q2: 112 <APOB<230 ng/ml
Q3: 230 <APOB<330 ng/ml
Q4: APOB>330 ng/ml
The patients’ characteristics in each defined quartile
are presented in Additional file 2: Table S2.
See statistical analysis section for further information.
Are apolipoprotein B gene expression and protein level
regulated in vitro by gonadotropins?
CG isolation
GC were isolated from FF samples, collected the day of
oocyte retrieval, as previously described [23]. Typically,
FF from 6 or 7 women (undergoing oocyte retrieval the
same day) with normal ovarian reserve were pooled and
centrifuged at 300 g for 5 min and at 500 g for 5 min,
successively. This experiment was performed 10 times
(n = 10). The cell layer was removed and re-suspended
in DMEM/F12 medium supplemented with 10 % foetal
calf serum (FCS) and antibiotics (100 UI/ml of penicillin
and 100 μg/ml streptomycin) (Invitrogen, France). Then,
to separate GC from cellular debris, the cell suspension
was centrifuged using a Puresperm gradient (Nidacon,
Mölndal, Sweden). The GC layer was collected, washed
and re-suspended in DMEM/F12 medium. In order to
eliminate macrophages, GC suspension was allowed to
settle for 20 min and the supernatant was centrifuged at
400 g for 30 min. The final pellet was re-suspended in
1 ml of DMEM/F12 medium and the cells suspension
was distributed in each well at a density of 2 × 105 cells.
Gonadotropin stimulation of GC primary culture
GC were cultured in DMEM/F12 medium supplemented
with 10 % FCS and antibiotics for 72 h to regain a more
native reaction pattern before hormonal stimulation
[24]. After three days in culture, GC were either un-
treated (control) or treated for 48 h with 30 ng/ml of r-
FSH (Puregon®, Schering Plough, Courbevoie, France) or
30 ng/ml of hCG (Ovitrelle ®, Merck Serono, Lyon,
France), individually or in combination. One μl of
Androstenedione (Sigma, Poole, UK) was added to the
culture medium to provide specific substrate to GC, for
oestrogen synthesis. Therefore, 17 β-estradiol quantifica-
tion by immuno-chemiluminescence using a commer-
cially kit (ADVIA® Centaur, Bayer Diagnostics,
Tarrytown, NY, USA) allowed to check GC viability
(Additional file 3: Figure S1). From day 3, FCS was re-
placed in culture medium by Nutridoma-CS (Roche Ap-
plied Science, Germany) in order to avoid lipoproteins
contamination. After 5 days of culture, culture medium
and GC samples were retrieved and stored at –80 °C.
Each culture’s experiment was performed in triplicate
and 10 times.
Quantitative (real-time) PCR: APOB gene expression in GC
Total RNA from GC was extracted using the Absolutely
RNA Microprep kit (ref 400805, Agilent Technologies,
Jolla, USA) according to manufacturer’s recommenda-
tions and quantified by Nanodrop ND-1000. By adding
10 μl of RT Buffer and 1 μl of RT Enzyme Mix, 200 ng
of total RNA was reverse-transcribed into cDNA using
the High Capacity RNA-to cDNA kit (Applied Biosys-
tems, Foster City, USA). Quantitative PCR was per-
formed from 5 μl of cDNA, 10 μl of Master Mix, 1 μl of
Master Assay and 4 μl of H2O, by using Taqman tech-
nology (Applied Biosystems, Foster City, USA). Each
qPCR reaction contained specific primers of APOB gene
(ref 4331182, ID assay: Hs00181142_m1; Applied Biosys-
tems). The human housekeeping GAPDH gene (ref
4351372, ID assay: Hs04420697_g1; Applied Biosystems)
was added in each qPCR template, as an endogenous
control to normalize relative APOB gene expression in
untreated (control) and treated GC samples. The
GAPDH housekeeping gene was stably expressed in GC
pools (n = 10) from different FF samples (Additional file
4: Figure S2). The APOB relative expression was calcu-
lated according to the equation 2−ΔΔCTmethod.
Western blot analysis: APOB protein expression in GC
After the addition of LDS Sample buffer and reducing
agent (Nupage, Invitrogen, France) to GC samples and
incubation at 95 °C for 10 min, each sample (containing
30 μg of total protein per well) was applied onto 4-12 %
polyacrylamide gradient gels (NuPage, Invitrogen,
France) inserted in a X-Cell SureLock system (Invitrogen,
France) and then blotted to nitrocellulose membranes
(Protan, Schleicher and Schuell, Dassel, Germany). The
membrane was saturated during one hour with Phosphate
Buffered Saline (PBS), 0.1 % Tween (PBS-T 0.1 %) and
5 % low-fat dried milk. An incubation was performed
overnight at 4 °C, with a rabbit polyclonal human
anti-ApoB100 antibody (H-300) (1:1000, sc- 25542,
Biotechnology, Santa Cruz, USA), in PBS-T 0.1 %. Then,
the membrane was incubated for one hour with an anti-
rabbit HRP antibody (Biotechnology, Santa Cruz, USA)
diluted in PBS-T 0.1 % (1:5000). APOB was detected
using Supersignal West Pico Trial kit (Thermoscientific,
Rockford, USA) and ChemiDocTM XRS Embellish-Images
LabTM 2.0 Software system (Bio-Rad).
Slot Blot analysis: APOB content of the culture medium
Culture medium samples (300 μl) were applied onto
nitrocellulose membrane (Protan, Schleicher and
Schuell, Dassel, Germany) and the membrane was
washed with Tris Buffer Saline (TBS) with 0.1 % of
Tween-20 (TBS-T 0.1 %), then saturated in TBS-T 0.1 %
containing 5 % low-fat dried milk for one hour. The in-
cubations were performed as described for western blots.
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Slot blots were detected using the Supersignal West Pico
Trial kit (Thermoscientific, Rockford, USA) and ana-
lyzed using the ChemiDocTM XRS Embellish-Images
LabTM 2.0 Software system (Bio-Rad).
Statistical analyses
The means ± standard deviations (SD) and 95 % confi-
dence intervals (CI) were reported for quantitative data
and percentages for categorical ones. The comparisons
of APOB concentrations according to IVF/ICSI out-
comes were performed using Student’s t-test. Then, sim-
ple linear regression models with robust variance
estimates for cluster-correlated data were performed to
analyze relationships between patients’ characteristics
and APOB concentration in FF. FF produced by the
same women defined the cluster. FF APOB concentra-
tion effects on IVF/ICSI outcomes were estimated using
univariate logistic regression. For each parameter, we
compared the model including APOB concentration as a
continuous variable with the model including APOB
concentration quartiles as qualitative variables, to select
and report the best one. The first quartile (Q1) was
taken as the reference for the comparison with the other
quartiles. Then, prognostic effect of patient’s characteris-
tics on IVF/ICSI outcomes was estimated using univari-
ate logistic regression models. Each variable with p < 0.2
was included in the multivariate logistic regression
models and used to estimate the independent effect of
APOB concentration in FF on IVF/ICSI outcomes. For
all these logistic regression models, robust variance esti-
mations for cluster-correlated data were used.
For in vitro studies, Mann-Whitney tests were used to
compare APOB gene expression in treated and untreated
GC.
Statistical analyses were performed using Stata 10.0
software. Results were considered significant when
p-value < 0.05.
Ethical approval
Ethical approval was obtained from the local Institu-
tional Review Board, CHU of Dijon, France.
Results
APOB is present in human follicular fluid and provides a
new biomarker to predict oocyte and embryo quality
Relationships between APOB concentrations in FF and
patient’s characteristics (age, BMI, number of attempts)
Follicular fluid from young patients (<36 years, n = 41)
contained significant higher APOB levels than FF ob-
tained from older patients (>36 years, n = 20) (β = –93.6,
p = 0.02). Likewise, APOB levels in FF were significantly
higher for patients with normal BMI compared to
underweight (BMI < 18.5 kg/m2) or obese patients
(BMI > 30 kg/m2) (β = –162.2, p = 0.001 and β = –142.3,
p = 0.005, respectively). In addition, FF related to women
enrolled in a first or second attempt contained higher
APOB levels than patients undergoing their third or
fourth attempt (β = –148.8, p = 0.005) (Table 1).
APOB concentrations in individual FF samples according to
IVF/ICSI outcomes
Amounts of APOB were detected in 201 individual
FF samples from pre-ovulatory follicles (mean ± SD:
244.6 ± 185.9 ng/ml, median: 229.3 ng/ml). In 90 % of
the samples analyzed (n = 182), APOB concentration
was under 480 ng/ml. Table 2 shows that APOB con-
centration was significantly higher in FF samples
containing an oocyte (n = 143) than those related to
empty zona pellucida (n = 58) (271 ± 181.8 ng/ml
versus 179 ± 181.3 ng/ml, p = 0.001, respectively). Like-
wise, FF samples related to normal fertilized oocytes
(n = 107, fertilization rate = 82.3 %, IC95 [75.7–89])
contained significant increased APOB levels compared
to those related to no fertilized oocytes (n = 23)
(279.8 ± 168.0 ng/ml versus 162.6 ± 192.5 ng/ml,
p = 0.004, respectively). APOB levels were significantly
also increased in FF samples associated with an em-
bryo on day 2 (n = 92) compared to those associated
with no embryo (n = 109) (294.3 ± 159.8 ng/ml versus
202.6 ± 196.5 ng/ml, p < 0.001, respectively).
Moreover, when considering APOB divided into
quartiles (Table 3), we found significant associations
between APOB concentrations in FF and the prob-
abilities to obtain an oocyte, a fertilized oocyte, an
embryo and a top quality embryo on day 2 (P = 0.001;
P < 0.001, P < 0.001, P = 0,047, respectively). Indeed if
APOB levels were equal or higher to 112 ng/ml (i.e.
including in Q2, Q3 or Q4), the odds of obtaining an
oocyte, a normal fertilized oocyte, an embryo or a top
quality embryo were significantly increased (Condi-
tional Odds Ratio, COR: 3.9, 4.2 and 3.9; COR: 6.2,
10.1 and 6.4; COR: 15.2, 15.5 and 8; COR: 4.4, 4.2,
Table 1 Relationships between APOB concentrations in human
FF and clinical prognostic markers of IVF success
Variable β Robust SE p-value
Age (years)
Age >36 versus≤ 36 –93.6 37.7 0.02
BMI (kg/m2)18.5≤ BMI < 25 (reference) − − −
BMI < 18.5 –162.2 48.0 0.001
25≤ BMI < 30 –59.0 72.7 NS
BMI≥ 30 –142.3 48.6 0.005
Number of attempts
3 and 4 versus 1 and 2 –148.8 51.3 0.005
BMI Body Mass Index, β regression coefficient, SE Standard Error, NS
No significant
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4.4 in Q2, Q3 and Q4, respectively). Moreover, after
adjustment for patients’ characteristics, if APOB con-
centrations were above 112 ng/ml and within the
ranges of Q2, Q3 or Q4, the probabilities of obtaining
an oocyte and a fertilized oocyte remained signifi-
cantly higher (AOR: 3.4, 3.3 and 3.4; AOR: 7.3, 11.2
and 6.3 in Q2, Q3 and Q4, respectively). However,
after adjustment for patient’s characteristics, the odds
of obtaining an embryo remained significantly ele-
vated only if APOB concentrations were included in
Q2 and Q3 (between 112 and 330 ng/ml) (AOR: 17.3,
15.5 in Q2 and Q3, respectively). Finally, the concen-
trations of APOB that could predict the odds of
obtaining a top quality embryo on day 2 (AOR = 4.8)
Table 2 Comparisons of APOB concentrations in human FF according to IVF/ICSI outcomes
FF related to n / number of FF
analyzed (%)
APOB (ng/ml) p-value
Mean ± SD [95 % CI]
Oocyte 143 / 201 (71.1) 271.0 ± 181.8 [240.9; 301.0] p = 0.001
Empty zona pellucida (no oocyte) 58 / 201 (28.9) 179.0 ± 181.3 [131.8; 227.2]
Normal fertilized oocytes 107 / 201 (53.2) 279.8 ± 168 [247.6; 312.0] p = 0.004
No fertilized oocytes 23 / 201 (11.4) 162.6 ± 192.5 [79.4; 245.8]
Embryo 92 / 201 (45.8) 294.3 ± 159.8 [261.2; 327.4] p < 0.001
No embryo 109 / 201(54.2) 202.6 ± 196.5 [165.3; 239.9]
Early cleavage 22 / 92 (23.9) 352.1 ± 192.6 [266.7; 437.5] NS
No early cleavage 70 / 92 (76.1) 276.1 ± 144.9 [241.6; 310.7]
Top quality embryo 45 / 92 (48.9) 322.1 ± 205.2 [260.4; 383.7] NS
No top quality embryo 47 / 92 (51.1) 267.7 ± 93.6 [240.2; 295.2]
Values are reported by the number of variable (n) / number of FF analyzed (percentage of the total). The comparisons were performed using Student’s t-test. SD
Standard Deviation, FF Follicular Fluid, NS No significant
Table 3 Probabilities of APOB concentration in human FF, divided into quartiles (Q), to predict IVF/ICSI outcomes
APOB quartiles (ng/ml) n / number of FF analyzed (%) P Crude OR [95 % CI] p-value Adjusted OR [95 % CI]a p-value
Probabilities of obtaining an oocyte
Q1 (<112) 24/50 (48.0) 0.001 – (reference) – (reference)
Q2 (≥112, <230) 40/51 (78.4) 3.9 [1.65–9.4] 0.002 3.4 [1.04–11.2] 0.044
Q3 (≥230, <330) 39/49 (79.6) 4.2 [1.73–10,3] 0.002 3.3 [1.19–9.08] 0.022
Q4 (≥330) 40/51 (78.4) 3.9 [1.65–9.4] 0.002 3.4 [1.01–11.44] 0.049
Probabilities of obtaining a fertilized oocyte
Q1(<112) 12/50 (24.0) <0.001 – (reference) – (reference)
Q2 (≥112, <230) 34/51 (66.7) 6.2 [1.79–21.76] 0.004 7.3 [1.59;33.43] 0.011
Q3 (≥230, <330) 33/49 (67.3) 10.1 [2.38–42.69] 0.002 11.2 [1.67;75.63] 0.013
Q4 (≥330) 28/51 (55.0) 6.4 [1.69–24.37] 0.006 6.3 [1.13;34.86] 0.035
Probabilities of obtaining an embryo on day 2
Q1(<112) 5/50 (10.0) <0.001 – (reference) – (reference)
Q2 (≥112, <230) 32/51 (62.8) 15.2 [5.11–44.95] <0.001 17.3 [2.2;137.1] 0.007
Q3 (≥230, <330) 31/49 (63.3) 15.5 [5.19–46.29] <0.001 15.5 [1.9;130.3] 0.011
Q4 (≥330) 24/51 (47.1) 8 [2.72–23.51] <0.001 8.3 [0.8;82.0] 0.071
Probabilities of obtaining a top quality embryo on day 2
Q1(<112) 4/50 (8.0) 0.047 – (reference) – (reference)
Q2 (≥112, <230) 14/51 (27.5) 4.4 [1.32–14.38] 0.016 4.8 [1.04;22.41] 0.045
Q3 (≥230, <330) 13/49 (26.5) 4.2 [1.24–13.86] 0.021 4.1 [0.75;22.64] NS
Q4 (≥330) 14/51 (27.4) 4.4 [1.32–14.38] 0.016 3.9 [0.64;23.91] NS
aProbabilities to obtain an oocyte and an embryo were adjusted for age and aetiology of infertility. Probabilities to obtain a fertilized oocyte and a top embryo
were adjusted for age. Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4. Q1 was considered as the reference. OR Odds Ratio, CI confidence intervals, FF
Follicular Fluid, NS No significant
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were comprised between 112 and 230 ng/ml (i.e. in-
cluding in Q2).
Regulation in vitro of apolipoprotein B gene and protein
by gonadotropins
APOB gene expression in GC stimulated by gonadotropins
APOB gene was significantly under-expressed in treated
human GC compared to untreated cells (control). In-
deed APOB gene expression decreased significantly after
a treatment by FSH, hCG or FSH and hCG compared to
control (p < 0.001; p < 0.001; p < 0.001, respectively).
Moreover, the down-regulation of APOB gene expres-
sion by FSH was significantly strengthened after intro-
duction of hCG into the culture medium (FSH versus
FSH and hCG, p = 0.019) (Fig. 1).
APOB protein expression in GC stimulated by
gonadotropins
As shown in Fig. 2a, an APOB band (APOB100) was de-
tected in human GC samples. The intensity of this band
was significantly decreased in GC stimulated by FSH,
hCG or FSH and hCG compared to unstimulated GC
(control) (p = 0.045; p = 0.009; p = 0.005, respectively)
(Fig. 2a and 2b). Moreover, APOB protein expression
was significantly lower in GC, treated simultaneously
with FSH and hCG compared to those treated only by
FSH (FSH versus FSH and hCG, p = 0.01) (Fig. 2b).
APOB protein content in the culture medium
Likewise, APOB was identified into culture medium
(Fig. 3). Low APOB secreted into culture medium was
found when GC were stimulated with gonadotropins,
compared to control (no treatment). The inhibitory
effect was synergized when the stimulation of GC was
performed with both, FSH and hCG (Fig. 3).
Discussion
This study investigated the relationships between APOB
concentrations in individual FF samples and IVF/ICSI out-
comes, and the hormonal regulation of APOB expression
in human cultured GC. Our results suggest that APOB
could be used as a non-invasive biomarker to predict oo-
cyte and embryo outcomes in patients undergoing IVF/
ICSI procedure. Moreover, APOB is down-regulated by
gonadotropins (FSH and hCG) which could influence
APOB content in ovarian follicle during COS. Several
clinical parameters influence IVF/ICSI prognostic and
outcomes. Interestingly, we showed that APOB concentra-
tion in FF was significantly related to some clinical charac-
teristics. Indeed, APOB level appeared to be significantly
higher in FF from women with good prognostic clinical
markers such as young age, normal BMI and first or sec-
ond IVF attempt. Aging is known to be associated with al-
terations of follicular environment and follicular cell
functions, resulting in a decrease of some metabolic
Fig. 1 APOB gene expression profile in human granulosa cells
treated with FSH, hCG individually or in combination, compared to
untreated cells (control) (*p < 0.001, **p < 0.001, ***p < 0.001, ****p =
0.019, respectively). The relative APOB gene expressions (±SD) were
reported for each culture’s condition performed in triplicates and
10 times
Fig. 2 a. Representative Western blot of APOB expression in human
granulosa cells treated with FSH, hCG, individually and in combination
compared to untreated cells (control); b. The APOB-100 band intensities
were compared between GC stimulated by FSH, hCG or FSH and hCG
and unstimulated GC (control) (*p= 0.045; **p= 0.009; ***p= 0.005,
respectively). FSH versus FSH and hCG, ****p= 0.01
Fig. 3 Representative slot blots of APOB content into culture medium
from granulosa cells treated with FSH, hCG, individually and in
combination compared to untreated cells (control)
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components present in the FF [25]. Accordingly, intra-
follicular APOB content could decrease with advanced
age, leading to harmful effects on oocyte and embryo de-
velopment. By contrast, one study reported low APOB
levels in FF from young women (<35 years) compared to
older women (>40 years) [20]. However, these results
included a very low number of patients (n = 5 for young
women; n = 4 for old women) compared to our study
(n = 61). Likewise, increasing BMI was also associated with
a decrease of APOB concentrations in FF which could be
related to the follicular environment impairment in obese
women at risk for poor reproductive performance [26].
One study investigated FF composition according to BMI
classification. However in this study, APOB was not de-
tected in the FF samples, most probably because of a low-
sensitivity of the APOB assay method used [27]. In
addition, it was reported that pregnancy rates decreased
with repeated IVF attempts [28]. Therefore, women en-
rolled in a first or second attempt, have clinical parame-
ters for prediction of success, related to a good health of
recruited ovarian follicles which contain higher APOB
concentrations. Moreover, the use of repeated ovarian
stimulation treatment could induce changes in the com-
position of the follicular fluid [29]. This could explain the
significant variations of intra-follicular APOB content ac-
cording to the number of IVF attempts. Some FF compo-
nents are involved in oocyte growth, oocyte
developmental competence and embryo development.
They provide non-invasive biomarkers of oocyte and/or
embryo quality [17, 18]. Likewise, we demonstrated that
APOB concentration in FF was significantly associated
with the probability to obtain an oocyte in the follicle, a
normal fertilization, an embryo and a top quality embryo,
respectively. Using a quartile model, we were able to dem-
onstrate that the intra-follicular APOB level could be used
to predict significantly and independently oocyte and em-
bryo outcomes. It is conceivable that APOB in FF could
play a role in the lipid transport as in plasma [1] and could
supplies cholesterol and triglycerides (TG) to oocytes for
supporting early embryo development. Indeed, TG act as
an energy source during oocyte maturation and potentially
during pre-implantation embryo development [30, 31].
Moreover, the pre-implantation embryo needs amounts of
cholesterol for membrane formation during its cell cleav-
ages [32–37]. Interestingly, LDL and VLDL receptors were
already identified on chicken and mouse oocytes [38–40],
but their presence have never been investigated in
humans. In addition, a very high intra-follicular APOB
level could affect embryo development and viability. In-
deed, it is noteworthy to mention that an APOB concen-
tration within the range of 112 and 230 ng/ml in FF
appeared to be the optimal dose to obtain a top quality
embryo. A large amount of APOB could reflect a lipid-
rich environment that could have a negative impact on
oocyte quality and thus embryo development [41]. In
addition, our data suggest that APOB could constitute a
new promising biomarker, offering an additional tool to
select the best embryo for replacement in order to im-
prove IVF success rates.
Moreover, we reported in a previous work that GC have
the ability to assemble and secrete ApoB100-containing li-
poproteins [13]. Therefore, the second part of this present
study consisted in understanding how the synthesis of
APOB by GC could be regulated by gonadotropins and
this knowing that these hormones are widely used in the
field of IVF when performing ovarian stimulation. We
showed that stimulation of cultured GC by gonadotropins
(FSH or/and hCG) modified APOB expression and led to
a significant decrease of its expression at the gene and
protein level. In addition, GC treatment by gonadotropins
reduced APOB protein content into the culture medium.
Here, we are for the first time demonstrating that gonado-
tropins can regulate APOB level in an in vitro GC model.
During IVF procedure, COS could contribute to modify
FF composition and thus GC secretions [29]. One of the
hypothesis would be that APOB is under-expressed in hu-
man GC upon a strong stimulation with gonadotropins.
This, would create a poor availability of APOB in the fol-
licular micro-environment leading to a disruption of lipid
transfer from GC to oocyte.
One can reasonable assume that a young woman with
good prognostic factors (normal BMI and first or second
attempt) will need less FSH doses during ovarian stimula-
tion than a woman with compromised prognostic factors
(older woman, overweight). Indeed, this has been con-
firmed in our prospective study where we found that the
“good prognosis” women needed lower dose of r-FSH
than the “bad prognosis” women (1892.4 ± 756.6 IU versus
2461 ± 932.46 IU, p = 0.006, respectively, data not shown).
Therefore, the results obtained from the experiments in
vitro (down regulation of APOB by FSH) could explain
why APOB level was found significantly lower in patients
with compromised prognostic factors compared to pa-
tients with good prognostic factors.
Conclusions
Our findings suggest that APOB could be easily quantified
in order to identify and select among the embryos, the
one that display all the morphological characteristics
needed for a pregnancy to occur. Hence, APOB could be
used as a prognostic biomarker when performing in vitro
fertilization. Moreover, we are reporting for the first time
a new regulation of APOB by gonadotropins in an in vitro
human GC model. APOB was found to be down-
regulated by gonadotropin treatment in cultured human
GC, suggesting a potential effect of COS on intra-
follicular fluctuation of APOB concentrations during IVF/
ICSI procedure.
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